CiPA Phase 1 ECG Biomarker Validation Study

• Sponsor: Food and Drug Administration (FDA) (U.S. Fed)
• Overall Status: Completed
• CT.gov ID: NCT03070470
• Collaborator: Spaulding Clinical Research LLC (Other)
• Enrollment: 60
• Location: 1
• Arms: 6
• Actual Duration (Months): 3.4
• Patients Per Site Per Month: 17.6

Study Details

Study Description

Brief Summary

This study will assess whether exposure response analysis of the electrocardiographic QTc and J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that drugs that predominantly block the potassium channel encoded by the human ether-à-go-go-related gene (hERG) with approximately equipotent late sodium and/or calcium block ("balanced ion channel" drugs) do not cause J-Tpeakc prolongation and that drugs that predominantly block hERG without late sodium or L-type calcium current block ("predominant hERG" drugs) cause QTc prolongation.

Condition or Disease	Intervention/Treatment	Phase
Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics	Drug: Ranolazine; Drug: Verapamil; Drug: Lopinavir / Ritonavir; Drug: Chloroquine; Drug: Placebo; Drug: Dofetilide and Diltiazem	Phase 1

Detailed Description

This study will assess whether exposure response analysis of the electrocardiographic QTc and J-Tpeakc intervals in Phase 1 clinical pharmacology studies can be used to confirm that "balanced ion channel" drugs do not cause J-Tpeakc prolongation and that "predominant hERG" drugs cause QTc prolongation. This clinical study consists of 2 parts: a 50-subject parallel part (Part 1) and a 10-subject crossover part (Part 2). Up to 74 healthy subjects will be enrolled (including 14 potential replacement subjects).

Part 1 will be a double-blind, randomized, placebo-controlled, 1 period parallel design to assess the effect of 4 marketed drugs and 1 placebo on the QTc and J-Tpeakc intervals in 50 healthy subjects. A parallel design similar to a single or multiple ascending dose (SAD/MAD) Phase 1 study will be used that will result in each study drug being administered to 10 subjects, and placebo to 10 subjects, in 1 period of 3 consecutive days to achieve low and high drug exposure.

Part 2 will be a double-blind, randomized, 2-period crossover design to assess the effect of hERG block (dofetilide) versus calcium block (diltiazem) on the QTc and J-Tpeakc intervals in 10 healthy subjects on Days 1, 2, and 3 (Period 1) and Days 8, 9, and 10 (Period 2).

Study Design

• Study Type: Interventional
• Actual Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: This clinical study consists of 2 parts: 50 subjects in Part 1 will be randomized to receive one of four drugs (ranolazine, verapamil, lopinavir / ritonavir, chloroquine) or placebo over 3 days. 10 subjects in Part 2 will be randomized to receive one of two treatment sequences (1. dofetilide or 2. diltiazem combined with dofetilide) over 3 days, then after washout, the subjects will receive the other treatment sequence over 3 days. Thus, Part 2 will have a cross-over component. A maximum of 14 additional replacement subjects may be enrolled.This clinical study consists of 2 parts:50 subjects in Part 1 will be randomized to receive one of four drugs (ranolazine, verapamil, lopinavir / ritonavir, chloroquine) or placebo over 3 days. 10 subjects in Part 2 will be randomized to receive one of two treatment sequences (1. dofetilide or 2. diltiazem combined with dofetilide) over 3 days, then after washout, the subjects will receive the other treatment sequence over 3 days. Thus, Part 2 will have a cross-over component. A maximum of 14 additional replacement subjects may be enrolled.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Other
• Official Title: Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)
• Actual Study Start Date: Mar 14, 2017
• Actual Primary Completion Date: Jun 26, 2017
• Actual Study Completion Date: Jun 26, 2017

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Ranolazine Ranolazine 1500 mg two times per day for 2.5 days	Drug: Ranolazine; Ranolazine 1500 mg orally two times per day for 2.5 days
Active Comparator: Verapamil Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3	Drug: Verapamil; Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
Active Comparator: Lopinavir / Ritonavir Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days	Drug: Lopinavir / Ritonavir; Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
Active Comparator: Chloroquine Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3	Drug: Chloroquine; Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
Placebo Comparator: Placebo Placebo capsules	Drug: Placebo; Placebo (administered orally)
Active Comparator: Dofetilide and Diltiazem In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.	Drug: Dofetilide and Diltiazem; In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.

Outcome Measures

Primary Outcome Measures

1. Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) [3 days]

   The primary outcome measure for the "balanced ion channel" drugs (ranolazine, verapamil, lopinavir / ritonavir) is for the upper bound of the 2-sided 90% confidence interval (CI) to be <10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model. Placebo drug concentration was set to 0 (see SAP).

2. Change From Baseline QTc With "Predominant hERG" Blocking Drug (Chloroquine) [3 days]

   The primary outcome measure for the "predominant hERG" drug (chloroquine) is for the upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model

3. QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide) [3 days]

   It will be assessed whether the projected QTc effect of dofetilide alone is significantly greater (i.e., p<0.05) than the projected QTc effect of the combination of dofetilide + diltiazem. This will be assessed at the dofetilide peak plasma level on Day 3 (computed from the combination of dofetilide + diltiazem) on the pooled dofetilide alone, diltiazem alone, and dofetilide + diltiazem data using a linear mixed effects model. Subsequently, and if the test is significant for QTc, the same test will be performed to assess calcium block (diltiazem) effects on J-Tpeakc.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 50 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion criteria:

1. Subject signs an institutional review board (IRB) approved written informed consent and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act [HIPAA] authorization) before any study related procedures are performed.

2. Subject is a healthy man or woman, 18 to 50 years of age, inclusive, who weighs at least 50 kg (110 pounds) and has a body mass index of 18 to 30 kg/m2, inclusive, at Screening.

3. Subject has normal medical history findings, clinical laboratory results, vital sign measurements, 12 lead ECG results, and physical examination findings at Screening or, if abnormal, the abnormality is not considered clinically significant (as determined and documented by the investigator or designee).

4. Female subjects will be at least 2 years postmenopausal, surgically sterile, or practicing 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique).

5. Female subjects must not be pregnant or lactating before enrollment in the study.

6. Male or female subjects must agree to practice 2 highly effective methods of birth control (as determined by the investigator or designee; one of the methods must be a barrier technique) from Screening until 30 days after the last dose of study drug.

7. Subject is highly likely (as determined by the investigator) to comply with the protocol defined procedures and to complete the study.

Exclusion criteria:

1. Subject has a safety 12 lead ECG result at Screening or Check in with evidence of any of the following abnormalities:

• QTc using Fridericia correction (QTcF) >430 msec

• PR interval >220 msec or <120 msec

• QRS duration >110 msec

• Second- or third-degree atrioventricular block

• Complete left or right bundle branch block or incomplete right bundle branch block

• Heart rate <50 or >90 beats per minute

• Pathological Q-waves (defined as Q wave >40 msec)

• Ventricular pre-excitation

1. Subject has more than 12 ectopic beats during the 3 hour Holter ECG at Screening.

2. Subject has a history of unexplained syncope, structural heart disease, long QT syndrome, heart failure, myocardial infarction, angina, unexplained cardiac arrhythmia, torsade de pointes, ventricular tachycardia, or placement of a pacemaker or implantable defibrillator. Subjects will also be excluded if there is a family history of long QT syndrome (genetically proven or suggested by sudden death of a close relative due to cardiac causes at a young age) or Brugada syndrome.

3. Subject has a history or current evidence of any clinically significant (as determined by the investigator) cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurologic, psychiatric, pulmonary, renal, urologic, and/or other major disease or malignancy (excluding nonmelanoma skin cancer). The investigator may allow exceptions to these criteria (e.g., cholecystectomy, childhood asthma) following discussion with the medical monitor.

4. Subject has a history of thoracic surgery.

5. Subject has any condition possibly affecting study drug absorption (e.g., gastrectomy, Crohn's disease, irritable bowel syndrome).

6. Subject has a skin condition likely to compromise ECG electrode placement.

7. Subject is a female with breast implants.

8. Subject's laboratory test results at Screening or Check in are outside the reference ranges provided by the clinical laboratory and considered clinically significant (as determined and documented by the investigator or designee).

9. Subject's laboratory test results at Screening or Check in indicate hypokalemia, hypocalcemia, or hypomagnesemia according to lower limits of the reference ranges provided by the clinical laboratory.

10. Subject's laboratory test results at Screening or Check in are >2 × the upper limit of normal (ULN) for alanine aminotransferase or aspartate aminotransferase, >1.5 × ULN for bilirubin, or >1.5 × ULN for creatinine.

11. Subject has a positive test result at Screening for human immunodeficiency virus I or II antibody, hepatitis C virus antibodies, or hepatitis B surface antigen.

12. Subject has a mean systolic blood pressure <100 or >140 mmHg or a mean diastolic blood pressure <50 or >90 mmHg at either Screening or Check in. Blood pressure will be measured in triplicate after the subject has been resting in a supine position for a minimum of 5 minutes.

13. Subject has a known hypersensitivity to any of the study drugs or related compounds.

14. Subject has consumed alcohol, xanthine containing products (e.g., tea, coffee, chocolate, cola), caffeine, grapefruit, or grapefruit juice within 48 hours before dosing or anticipates an inability to abstain from these products throughout the duration of the study.

15. Subject has used nicotine containing products (e.g., cigarettes, cigars, chewing tobacco, snuff) within 6 weeks before Screening (self reported).

16. Subject is unable to tolerate a controlled, quiet, study conduct environment, including avoidance of music, television, movies, games, and activities that may cause excitement, emotional tension, or arousal during the prespecified time points (e.g., before and during ECG extraction windows).

17. Subject is unwilling to comply with study rules, including the study-specific diet, attempting to void at specified times (e.g., before ECG extraction windows), remaining quiet, awake, undistracted, motionless, and supine during specified times, and avoiding vigorous exercise as directed.

18. Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months before Screening, has a history of alcoholism or drug/chemical/substance abuse within 2 years before Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine, or 1 ounce of spirits/hard liquor), or has a positive test result for alcohol or drugs of abuse at Screening or Check in.

19. Subject has used any prescription or nonprescription drugs (including aspirin or nonsteroidal anti inflammatory drugs [NSAIDs] and excluding oral contraceptives and acetaminophen) within 14 days or 5 half lives (whichever is longer), or complementary and alternative medicines within 28 days before the first dose of study drug.

20. Subject is currently participating in another clinical study of an investigational drug or has been treated with any investigational drug within 30 days or 5 half-lives (whichever is longer) of the compound.

21. Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days, or donated plasma within 7 days before Check in.

22. Subject has any other condition that precludes his or her participation in the study (as determined by the investigator).

23. Subject is unwilling to have genetic analysis performed or a blood sample collected for isolating peripheral blood mononuclear cells (PBMCs).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Spaulding Clinical Research	West Bend	Wisconsin	United States	53095

Sponsors and Collaborators

• Food and Drug Administration (FDA)
• Spaulding Clinical Research LLC

Investigators

• Principal Investigator: Carlos Sanabria, MD, Spaulding Clinical Research LLC

Study Documents (Full-Text)

• Study Protocol - Mar 24, 2017
• Statistical Analysis Plan - Mar 25, 2017

More Information

Publications

• Vicente J, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, Matta MK, Li Z, Liu J, Garnett C, Stockbridge N, Zineh I, Strauss DG. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study. Clin Pharmacol Ther. 2018 Jan;103(1):54-66. doi: 10.1002/cpt.896. Epub 2017 Nov 16. Review.
• Vicente J. Update on the ECG component of the CiPA initiative. J Electrocardiol. 2018 Nov - Dec;51(6S):S98-S102. doi: 10.1016/j.jelectrocard.2018.08.003. Epub 2018 Aug 7. Review.

• Responsible Party: Food and Drug Administration (FDA)
• ClinicalTrials.gov Identifier: NCT03070470
• Other Study ID Numbers: 16-086D; SCR-004
• First Posted: Mar 3, 2017
• Last Update Posted: Jan 18, 2020
• Last Verified: Jan 1, 2020

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Additional relevant MeSH terms: Long QT Syndrome; Ritonavir; Lopinavir; Chloroquine; Verapamil; Dofetilide; Diltiazem; Ranolazine

Study Results

Participant Flow

Arm/Group Title	Ranolazine	Verapamil	Lopinavir / Ritonavir	Chloroquine	Placebo	Dofetilide and Diltiazem
Arm/Group Description	Ranolazine 1500 mg two times per day for 2.5 days Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days	Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)	Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days	Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)	Placebo capsules Placebo: Placebo (administered orally)	In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10. Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Period Title: Overall Study
STARTED	10	10	10	10	10	10
COMPLETED	10	9	10	10	10	8
NOT COMPLETED	0	1	0	0	0	2

Baseline Characteristics

Arm/Group Title	Ranolazine	Verapamil	Lopinavir / Ritonavir	Chloroquine	Placebo	Dofetilide and Diltiazem	Total
Arm/Group Description	Ranolazine 1500 mg two times per day for 2.5 days Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days	Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)	Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days	Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)	Placebo capsules Placebo: Placebo (administered orally)	In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10. Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.	Total of all reporting groups
Overall Participants	10	10	10	10	10	10	60
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	33.8 (8.0)	28.2 (7.9)	32.6 (11.1)	28.8 (8.8)	33.3 (9.0)	33.4 (7.2)	31.7 (8.7)
Sex: Female, Male (Count of Participants)
Female	2 20%	4 40%	6 60%	3 30%	2 20%	5 50%	22 36.7%
Male	8 80%	6 60%	4 40%	7 70%	8 80%	5 50%	38 63.3%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%	1 10%	2 20%	1 10%	4 6.7%
Not Hispanic or Latino	10 100%	9 90%	10 100%	9 90%	8 80%	9 90%	55 91.7%
Unknown or Not Reported	0 0%	1 10%	0 0%	0 0%	0 0%	0 0%	1 1.7%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	1 10%	1 10%	0 0%	1 10%	1 10%	0 0%	4 6.7%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	6 60%	5 50%	5 50%	7 70%	5 50%	4 40%	32 53.3%
White	3 30%	4 40%	5 50%	2 20%	4 40%	6 60%	24 40%
More than one race	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%	0 0%
Region of Enrollment (Count of Participants)
United States	10 100%	10 100%	10 100%	10 100%	10 100%	10 100%	60 100%
Weight (Kg) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Kg]	80.3 (11.1)	77.1 (10.2)	76.2 (6.1)	72.4 (11.3)	77.5 (15.6)	69.5 (9.4)	75.5 (11.1)
Systolic Blood Pressure (mmHg) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [mmHg]	116.6 (9.5)	109.2 (6.6)	119.4 (10.0)	114.8 (8.1)	116.6 (6.4)	113.4 (8.2)	115.0 (8.5)
Diastolic Blood Pressure (mmHg) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [mmHg]	66.7 (8.7)	63.4 (6.9)	67.3 (8.5)	66.9 (5.5)	66.7 (9.0)	64.2 (6.9)	65.9 (7.5)
Heart Rate (BPM) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [BPM]	59.8 (8.9)	63.6 (9.8)	61.3 (9.3)	59.2 (9.5)	58.6 (5.6)	61.9 (6.1)	60.7 (8.2)
PR Interval (ms) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ms]	182.4 (23.9)	178.4 (16.2)	162.3 (16.5)	159.1 (15.5)	164.4 (15.0)	171.6 (19.4)	169.7 (19.2)
QRS Duration (ms) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ms]	90.1 (7.7)	82.9 (8.2)	87.1 (5.8)	84.7 (6.7)	85.4 (11.5)	87.3 (9.4)	86.3 (8.4)
QTc (Fridericia's heart rate corrected QT interval) (ms) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ms]	386.0 (20.2)	386.5 (17.8)	383.9 (17.1)	393.3 (20.0)	387.1 (13.7)	397.1 (26.1)	389.0 (19.2)
J-Tpeakc (heart rate corrected J-Tpeak interval) (ms) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ms]	227.7 (22.7)	239.4 (22.4)	231.0 (14.5)	238.7 (20.3)	229.5 (24.2)	239.7 (29.4)	234.3 (22.3)
Tpeak-Tend interval (ms) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ms]	68.7 (7.9)	65.1 (6.6)	65.7 (7.9)	69.7 (8.7)	72.5 (6.4)	70.6 (14.8)	68.7 (9.2)

Outcome Measures

1. Primary Outcome

Title	Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir)
Description	The primary outcome measure for the "balanced ion channel" drugs (ranolazine, verapamil, lopinavir / ritonavir) is for the upper bound of the 2-sided 90% confidence interval (CI) to be <10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model. Placebo drug concentration was set to 0 (see SAP).
Time Frame	3 days

Outcome Measure Data

Analysis Population Description

Placebo data was used in the statistical analysis to account for placebo effect. Chloroquine, and dofetilide and diltiazem data were collected but not part of the primary J-Tpeakc analysis. The underlying raw data (available at https://doi.org/10.13026/C2967M) were the input in the statistical analysis. Summary included per PRS review team request.

Arm/Group Title	Ranolazine	Verapamil	Lopinavir / Ritonavir	Chloroquine	Placebo	Dofetilide and Diltiazem
Arm/Group Description	Ranolazine 1500 mg two times per day for 2.5 days Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days	Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)	Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days	Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)	Placebo capsules Placebo: Placebo (administered orally)	In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10. Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Measure Participants	10	10	10	0	10	0
Median (Full Range) [ms]	-8.3	-7.8	-11.5	-10.9

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Ranolazine, Placebo
	Comments	Upper bound of the 2-sided 90% confidence interval (CI) to be <10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model
	Type of Statistical Test	Other
	Comments	The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	1.2
	Confidence Interval	(2-Sided) 90%; -9.5 to 12.0
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	Verapamil, Placebo
	Comments	Upper bound of the 2-sided 90% confidence interval (CI) to be <10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model
	Type of Statistical Test	Other
	Comments	The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-2.6
	Confidence Interval	(2-Sided) 90%; -11.4 to 6.1
	Parameter Dispersion	Type: Value:
	Estimation Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	Lopinavir / Ritonavir, Placebo
	Comments	Upper bound of the 2-sided 90% confidence interval (CI) to be <10 msec for the projected placebo-corrected change from baseline J-Tpeakc effect at the peak plasma level on Day 3 using a linear mixed-effects exposure response model
	Type of Statistical Test	Other
	Comments	The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	-2.9
	Confidence Interval	(2-Sided) 90%; -14.6 to 8.8
	Parameter Dispersion	Type: Value:
	Estimation Comments

2. Primary Outcome

Title	Change From Baseline QTc With "Predominant hERG" Blocking Drug (Chloroquine)
Description	The primary outcome measure for the "predominant hERG" drug (chloroquine) is for the upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model
Time Frame	3 days

Outcome Measure Data

Analysis Population Description

Ranolazine, verapamil, lopinavir/ritonavir, and dofetilide and diltiazem data were collected but not part of the primary QTc analysis. The underlying raw data (available at https://doi.org/10.13026/C2967M) were the input in the statistical analysis. Median and range summary included per PRS review team request.

Arm/Group Title	Ranolazine	Verapamil	Lopinavir / Ritonavir	Chloroquine	Placebo	Dofetilide and Diltiazem
Arm/Group Description	Ranolazine 1500 mg two times per day for 2.5 days Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days	Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)	Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days	Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)	Placebo capsules Placebo: Placebo (administered orally)	In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10. Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Measure Participants	0	0	0	10	10	0
Median (Full Range) [ms]	17.7	-9.3

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	Chloroquine, Placebo
	Comments	Upper bound of the 2-sided 90% CI to be ≥10 msec for the projected placebo-corrected change from baseline QTc effect at the peak plasma level on Day 1 using a linear mixed-effects exposure response model.
	Type of Statistical Test	Other
	Comments	The appropriateness of the linear model will be assessed. Projected estimates will be computed only if the linear model is found acceptable.
Statistical Test of Hypothesis	p-Value
	Comments
	Method
	Comments
Method of Estimation	Estimation Parameter	Mean Difference (Final Values)
	Estimated Value	30.7
	Confidence Interval	(2-Sided) 90%; 22.6 to 38.9
	Parameter Dispersion	Type: Value:
	Estimation Comments

3. Primary Outcome

Title	QTc Shortening From Calcium Block (Diltiazem) in the Presence of hERG Block (Dofetilide)
Description	It will be assessed whether the projected QTc effect of dofetilide alone is significantly greater (i.e., p<0.05) than the projected QTc effect of the combination of dofetilide + diltiazem. This will be assessed at the dofetilide peak plasma level on Day 3 (computed from the combination of dofetilide + diltiazem) on the pooled dofetilide alone, diltiazem alone, and dofetilide + diltiazem data using a linear mixed effects model. Subsequently, and if the test is significant for QTc, the same test will be performed to assess calcium block (diltiazem) effects on J-Tpeakc.
Time Frame	3 days

Outcome Measure Data

Analysis Population Description

QTc, J-Tpeakc, and drug concentration data from all subjects in the dofetilide and diltiazem arm. Ranolazine, verapamil, lopinavir/ritonavir, chloroquine, and placebo data were collected but not part of this analysis (see SAP). The underlying raw data were the input in the statistical analysis. Summary included per PRS review team request.

Arm/Group Title	Ranolazine	Verapamil	Lopinavir / Ritonavir	Chloroquine	Placebo	Dofetilide	Diltiazem+Dofetilide
Arm/Group Description	Ranolazine 1500 mg two times per day for 2.5 days Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days	Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)	Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days	Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)	Placebo capsules Placebo: Placebo (administered orally)	Data from the Dofetilide alone period of the crossover part: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.	Data from the diltiazem and dofetilide period of the crossover part: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
Measure Participants	0	0	0	0	0	10	10
Median (Full Range) [ms]	2.2	-1.7

Adverse Events

Time Frame	4 days
Adverse Event Reporting Description	MedDRA
Arm/Group Title	Ranolazine		Verapamil		Lopinavir / Ritonavir		Chloroquine		Placebo		Dofetilide and Diltiazem
Arm/Group Description	Ranolazine 1500 mg two times per day for 2.5 days Ranolazine: Ranolazine 1500 mg orally two times per day for 2.5 days		Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 Verapamil: Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)		Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days Lopinavir / Ritonavir: Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days		Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 Chloroquine: Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)		Placebo capsules Placebo: Placebo (administered orally)		In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10. Dofetilide and Diltiazem: In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3. In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10.
All Cause Mortality
	Ranolazine		Verapamil		Lopinavir / Ritonavir		Chloroquine		Placebo		Dofetilide and Diltiazem
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Serious Adverse Events
	Ranolazine		Verapamil		Lopinavir / Ritonavir		Chloroquine		Placebo		Dofetilide and Diltiazem
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Other (Not Including Serious) Adverse Events
	Ranolazine		Verapamil		Lopinavir / Ritonavir		Chloroquine		Placebo		Dofetilide and Diltiazem
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	3/10 (30%)		5/10 (50%)		9/10 (90%)		4/10 (40%)		2/10 (20%)		8/10 (80%)
Cardiac disorders
Atrioventricular Block Second Degree	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		2/10 (20%)
Bradycardia	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)
Palpitations	1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Eye disorders
Chalazion	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)
Gastrointestinal disorders
Abdominal Discomfort	0/10 (0%)		0/10 (0%)		3/10 (30%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Abdominal Distention	0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Constipation	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)
Diarrhoea	0/10 (0%)		1/10 (10%)		5/10 (50%)		1/10 (10%)		1/10 (10%)		0/10 (0%)
Flatulence	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)
Gastroesophageal Reflux Disease	0/10 (0%)		0/10 (0%)		2/10 (20%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Vomiting	0/10 (0%)		0/10 (0%)		2/10 (20%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
General disorders
Cold Sweat	1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Decreased Appetite	0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)
Dry Mouth	0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Dysgeusia	0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Headache	0/10 (0%)		2/10 (20%)		5/10 (50%)		1/10 (10%)		0/10 (0%)		3/10 (30%)
Nausea	0/10 (0%)		0/10 (0%)		4/10 (40%)		1/10 (10%)		0/10 (0%)		2/10 (20%)
Presyncope	0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Somnolence	1/10 (10%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Musculoskeletal and connective tissue disorders
Back Pain	0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Nervous system disorders
Dizziness	0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		1/10 (10%)
Psychiatric disorders
Dissociation	1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Reproductive system and breast disorders
Menstrual Discomfort	0/10 (0%)		0/10 (0%)		1/10 (10%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Respiratory, thoracic and mediastinal disorders
Nasal Congestion	0/10 (0%)		0/10 (0%)		2/10 (20%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Pharyngitis	1/10 (10%)		0/10 (0%)		2/10 (20%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Skin and subcutaneous tissue disorders
Skin Burning Sensation	0/10 (0%)		0/10 (0%)		2/10 (20%)		0/10 (0%)		0/10 (0%)		0/10 (0%)
Skin Reaction	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		2/10 (20%)
Vascular disorders
Vessel Puncture Site Pain	0/10 (0%)		0/10 (0%)		2/10 (20%)		0/10 (0%)		0/10 (0%)		1/10 (10%)
Vessel Puncture Site Phlebitis	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)
Vessel Puncture Site Swelling	0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		0/10 (0%)		1/10 (10%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.